<DOC>
	<DOCNO>NCT00244192</DOCNO>
	<brief_summary>The purpose study determine whether infliximab effective fat-free mass treatment patient moderate severe COPD suffering cachexia .</brief_summary>
	<brief_title>Effects Infliximab ( Remicade ) Fat Free Mass Patients With Moderate Severe COPD Suffering From Cachexia</brief_title>
	<detailed_description>COPD multicomponent disease characterize abnormal inflammatory response lung noxious particle accompany systemic effect like weight loss , muscle wasting , reduce functional capacity health status . A persistent systemic inflammatory response reflect enhanced level acute phase protein like C-reactive protein ( CRP ) pro-inflammatory cytokine tumor necrosis factor ( TNF ) - α , present COPD . There several study indicate increase systemic inflammator response associate weight loss , cachexia ( loss fat-free muscle mass ) , physical function health status . Cachexia associate systemivc inflammation always readily overcome nutritional intervention alone . The hypothesis study infliximab therapy ( 3 infusion 5 mg/kg infliximab placebo 1:1 week 0 , 2 6 ) increase fat-free mass relatively placebo decrease inflammation . Secondary endpoint : lung function , muscle function , exercise capacity health status . On week 8 , 12 26 follow-up measurement do .</detailed_description>
	<mesh_term>Cachexia</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>1 . COPD acording GOLD FEV1/FVC ratio &lt; 70 % , postbronchodilator FEV1 &gt; 20 % &lt; 80 % predict FEV1 &gt; 500ml . 2 . Fat Free Mass Index : &lt; 17.5 kg/m2 male , &lt; 15 kg/m2 female . 3 . Symptomatic ( eg , chronic cough , sputum production , shortness breath ) least 2 month 4 . &gt; = 40 year age ≤ 80 year age 5 . History &gt; =10 pack year smoke 6 . Men woman childbearing potential must use adequate birth control measure least one month prior screen duration study continue precaution 6 month receive last infusion . 7 . Ability adhere study visit schedule protocol requirement 8 . Provide sign , write informed consent prior participation study 9 . Be adequately immunized S. pneumoniae . Patients enrol study autumn winter month immunize influenza 10 . The screen laboratory test result must meet following criterion : 1 . Hemoglobin &gt; = 8.5 g/dL 2 . WBC &gt; = 3.5 x 109/L 3 . Neutrophils &gt; = 1.5 x 109/L 4 . Platelets &gt; = 100 x 109/L 5 . SGOT ( AST ) alkaline phosphatase level must within 3 time upper limit normal range laboratory conduct test . 6 . TSH within normal range 0.3 5 mIU/L . 11 . Are consider eligible accord tuberculosis ( TB ) eligibility assessment , screening , early detection reactivation rule 1 . &gt; 11 % increase FEV1 % predict fix dose bronchodilator ( 200 µg inhale salbutamol ) 2 . &gt; 12 % variation screen baseline FEV1 assessments 3 . FEV1 &lt; 500 ml 4 . Patients asthma main component obstructive airway disease 5 . Moderate severe exacerbation COPD within previous 2 month 6 . History clinical sign severe cor pulmonale , pulmonary hypertension , severe right left side cardiac failure , serious arrhythmia , myocardial infarction cardiac intervention within 6 month screen . Exclusion criterion echocardiogram : Exclude patient right–sided heart defect , define 1 follow 3 echocardiography criterion : 1 . Right ventricular size increase , inlet diameter &gt; 5cm 2 . Moderatetosevere tricuspid valve regurgitation 3 . Right ventricular ( RV ) right atrial ( RA ) pressure drop &gt; 50 mmHg Exclusion patient leave ventricular ejection fraction ( LV EF ) &lt; 40 % , measure echocardiography . Exclusion criterion electrocardiogram : Exclude patient follow arrhythmias identify electrocardiography ( ECG ) : 1 . Fast atrial fibrillation ventricular rate &gt; 90/min 2 . Atrialventricular conduction delay grade 2 high : excludes 2nd 3rd degree heart block . 3 . Left bundle branch block , QRS complex &gt; 120msec . 4 . Ventricular arrhythmia : ventricular tachycardia trigeminy . 7 . Chronic respiratory failure ( PaO2 &lt; 7.3kPa without hypercapnia ) patient require long term oxygen therapy . 8 . Participation acute phase pulmonary rehabilitation program within 4 week prior screen plan participation pulmonary rehabilitation study 9 . Stopping smoke attend smoke cessation class within 6 week enrollment . 10 . Known a1 antitrypsin deficiency 11 . Serious acute infection ( eg , hepatitis , pneumonia pyelonephritis ) previous 3 month 12 . Major surgery previous 3 month 13 . Women pregnant , nursing , plan pregnancy within one year screening ( i.e. , approximately 6 month follow last infusion ) 14 . Use investigational drug within 1 month prior screen within 5 half ? live investigational agent , whichever longer 15 . Treatment therapeutic agent target reduce TNFa ( e.g . pentoxifylline , thalidomide , etanercept , etc . ) within 3 month screen . Treatment immunosuppressive cytotoxic therapy . 16 . Previous administration infliximab 17 . Known allergy murine product 18 . Are consider ineligible accord TB eligibility assessment , screening , early detection reactivation rule define Section 4.3 . 19 . Have opportunistic infection ( eg , herpes zoster [ shingle ] , cytomegalovirus , Pneumocystis carinii , aspergillosis , histoplasmosis , mycobacteria TB ) within 6 month prior screen . 20 . Have chest radiograph screening show evidence malignancy , infection , abnormality suggestive TB 21 . Have opportunistic infection ( e.g . herpes zoster [ shingle ] , cytomegalovirus , Pneumocystis carinii , aspergillosis , histoplasmosis , mycobacteria TB ) within 6 month screen . 22 . Documented HIV infection . 23 . Positive serology active hepatitis B C base subject test screen . A positive result indicate referral consultant Hepatologist investigation support . 24 . Have current sign symptom severe , progressive uncontrolled renal , hepatic , hematological , gastrointestinal , endocrine , cardiac , neurologic , cerebral disease ( include demyelinate disease multiple sclerosis ) 25 . Presence transplant organ ( exception corneal transplant &gt; 3 month prior screen ) 26 . Malignancy within past 5 year ( except squamous basal cell carcinoma skin treat evidence recurrence ) 27 . History lymphoproliferative disease include lymphoma , sign symptom suggestive possible lymphoproliferative disease , lymphadenopathy unusual size location ( nodes posterior triangle neck , infra ? clavicular , epitrochlear , periaortic area ) , splenomegaly 28 . Known recent substance abuse ( drug alcohol ) 29 . Poor tolerability venipuncture lack adequate venous access require blood sample study period 30 . Known atypical mycobacterium infection</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2005</verification_date>
	<keyword>COPD</keyword>
	<keyword>infliximab</keyword>
	<keyword>Remicade</keyword>
	<keyword>inflammation</keyword>
	<keyword>cachexia</keyword>
	<keyword>fat-free mass</keyword>
	<keyword>health status</keyword>
	<keyword>exercise capacity</keyword>
</DOC>